Blog
FDA updates, drug pricing news, insurance coverage changes, and the latest clinical trial results for GLP-1 weight loss medications.
Small-molecule GLP-1 drugs penetrate deep into the brain to suppress pleasure-based eating and potentially addiction by targeting the central amygdala.
The DoseFDA proposes excluding semaglutide, tirzepatide, and liraglutide from 503B bulk compounding list, effectively ending affordable compounded alternatives that cost $200-400 monthly versus $1000+ for brand drugs.
The DoseFDA proposes excluding semaglutide, tirzepatide, and liraglutide from 503B bulk drug list, effectively ending large-scale compounding of affordable GLP-1 alternatives that cost $200-400 monthly vs $1000+ for brand drugs.
The DoseEli Lilly's Foundayo becomes second FDA-approved GLP-1 pill with no food or timing restrictions, launching at $149/month through record-fast approval process.
The DoseNovo Nordisk's Wegovy pill launch has doubled telehealth provider business overnight and reached tens of thousands of new patients, challenging expectations about Eli Lilly's GLP-1 market leadership.
The DoseCMS will provide Medicare beneficiaries access to Wegovy, Zepbound, and Foundayo for $50/month starting July 1, 2026, marking the first time Medicare covers weight loss medications.
The DoseJohns Hopkins analysis of 175,000 Type 1 diabetes patients shows GLP-1 drugs reduce heart disease risk by 15% and kidney failure by 19% without safety concerns.
The DoseMedicare's temporary GLP-1 coverage program gets 18-month extension while the permanent BALANCE model faces uncertainty over insurer participation.
The DoseNovo Nordisk's Ozempic pill launches May 4 with self-pay pricing starting at $149/month, offering the first oral diabetes option under the Ozempic brand.
The DoseThe FDA proposed removing semaglutide, tirzepatide, and liraglutide from its 503B bulks list, potentially ending large-scale compounding of affordable GLP-1 alternatives for good.
The DoseThe FDA will hold its first public meeting on June 4 to review the Commissioner's National Priority Voucher program that has cut drug approval times from 10-12 months to just 1-2 months.
